Activation of LXRα improves cardiac remodeling induced by pulmonary artery hypertension in rats.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      Hydrocarbons, Fluorinated/*administration & dosage ; Hypertension, Pulmonary/*complications ; Hypertrophy, Right Ventricular/*drug therapy ; Liver X Receptors/*metabolism ; Sulfonamides/*administration & dosage; Animals ; Disease Models, Animal ; Gene Expression Regulation/drug effects ; Humans ; Hydrocarbons, Fluorinated/pharmacology ; Hypertension, Pulmonary/genetics ; Hypertension, Pulmonary/metabolism ; Hypertrophy, Right Ventricular/genetics ; Hypertrophy, Right Ventricular/metabolism ; Interleukin-6/genetics ; Interleukin-6/metabolism ; NF-kappa B/genetics ; NF-kappa B/metabolism ; Nitric Oxide Synthase Type II/genetics ; Nitric Oxide Synthase Type II/metabolism ; Rats ; Sulfonamides/pharmacology ; Tumor Necrosis Factor-alpha/genetics ; Tumor Necrosis Factor-alpha/metabolism
    • Abstract:
      Inflammatory factors regulated by NF-κB play a significant role in PAH and myocardial hypertrophy. LXR activation may inhibit myocardial hypertrophy via suppressing inflammatory pathways; it is unknown whether LXR is also involved in PAH-induced myocardial hypertrophy or remodeling. To further explore the protective effect of LXR in PAH-induced cardiac hypertrophy and remodeling, a PAH model was developed, and T0901317, an agonist of LXR, was used to examine the effect of LXR activation. PAH rats demonstrated obvious cardiac hypertrophy and remodeling in the right ventricle, but significant improvement of cardiac hypertrophy and remodeling was observed in PAH rats treated with T0901317. Through RT-PCR, Western blot and ELISA examination, NF-κB, IL-6, TNF-α, and iNOS were found to be significantly reduced in PAH rats treated with T0901317 compared to PAH rats treated with DMSO. Apoptosis was also significantly reduced in PAH rats treated with T0901317. Thus, LXR activation may inhibit PAH-induced cardiac hypertrophy and remodeling by inhibiting NF-κB-mediated inflammatory pathways.
    • References:
      Hypertension. 2008 Jun;51(6):1631-6. (PMID: 18443233)
      J Rheumatol. 1990 May;17(5):656-62. (PMID: 2359076)
      Science. 2000 Sep 1;289(5484):1524-9. (PMID: 10968783)
      Sci Rep. 2016 Nov 11;6:37001. (PMID: 27833156)
      J Mol Endocrinol. 2004 Dec;33(3):609-22. (PMID: 15591022)
      Circulation. 1978 Dec;58(6):1204-11. (PMID: 709777)
      Circulation. 1981 Jan;63(1):87-95. (PMID: 7438411)
      Circ Res. 2007 Jul 6;101(1):40-9. (PMID: 17540978)
      Circ Heart Fail. 2014 Nov;7(6):1032-41. (PMID: 25277999)
      Shock. 2011 Apr;35(4):367-74. (PMID: 20926989)
      Genes Dev. 1995 May 1;9(9):1033-45. (PMID: 7744246)
      Cell Metab. 2010 Aug 4;12 (2):187-93. (PMID: 20674863)
      Eur J Heart Fail. 2015 Mar;17 (3):273-82. (PMID: 25684370)
      Atherosclerosis. 2014 Jan;232(1):1-9. (PMID: 24401210)
      Eur J Heart Fail. 2010 Oct;12 (10 ):1042-50. (PMID: 20587624)
      N Engl J Med. 2004 Sep 30;351(14):1425-36. (PMID: 15459304)
      Cardiovasc Diabetol. 2014 Nov 22;13:149. (PMID: 25416469)
      Circ Res. 2002 Nov 29;91(11):988-98. (PMID: 12456484)
      J Magn Reson Imaging. 2007 Jun;25(6):1283-7. (PMID: 17520735)
      EMBO Mol Med. 2015 Jul 09;7(9):1229-43. (PMID: 26160456)
      J Immunol. 2008 Nov 15;181(10 ):7176-85. (PMID: 18981139)
      Am J Physiol. 1988 Dec;255(6 Pt 2):H1484-91. (PMID: 3144186)
      Transl Res. 2013 Feb;161(2):110-7. (PMID: 23146569)
      Mol Cell Biol. 1994 Oct;14 (10 ):7025-35. (PMID: 7935418)
      Cell. 1998 May 29;93(5):693-704. (PMID: 9630215)
      Cardiovasc Res. 2015 Jul 1;107(1):78-88. (PMID: 25998987)
      Am J Physiol Heart Circ Physiol. 2012 Apr 15;302(8):H1655-66. (PMID: 22245771)
      Inflammation. 2011 Dec;34(6):698-706. (PMID: 21136146)
      Cell. 1995 Feb 24;80(4):573-82. (PMID: 7867065)
      Cardiovasc Res. 2009 Oct 1;84(1):119-26. (PMID: 19487338)
      J Am Coll Cardiol. 2002 May 1;39(9):1450-5. (PMID: 11985906)
      Nat Med. 2003 Feb;9(2):213-9. (PMID: 12524534)
      Acta Histochem. 2014 Jan;116(1):214-21. (PMID: 23915475)
      J Biol Chem. 2003 Mar 21;278(12 ):10443-9. (PMID: 12531895)
      J Clin Invest. 2006 Mar;116(3):607-14. (PMID: 16511593)
      Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):403-8. (PMID: 21173252)
      Basic Res Cardiol. 2013 Jan;108(1):323. (PMID: 23266787)
      J Biol Chem. 2009 Oct 30;284(44):30113-21. (PMID: 19717840)
    • Accession Number:
      0 (Hydrocarbons, Fluorinated)
      0 (Il6 protein, rat)
      0 (Interleukin-6)
      0 (Liver X Receptors)
      0 (NF-kappa B)
      0 (Nr1h3 protein, rat)
      0 (Sulfonamides)
      0 (T0901317)
      0 (Tumor Necrosis Factor-alpha)
      EC 1.14.13.39 (Nitric Oxide Synthase Type II)
      EC 1.14.13.39 (Nos2 protein, rat)
    • Publication Date:
      Date Created: 20170723 Date Completed: 20190225 Latest Revision: 20220208
    • Publication Date:
      20240829
    • Accession Number:
      PMC5522383
    • Accession Number:
      10.1038/s41598-017-04640-6
    • Accession Number:
      28733583